Part 2Continue reading
Category Archives: Uncategorized
Washington Watch – H.R. 3 and Last Minute USMCA Change Deliver 1-2 Punch on Life Science Innovation
Life Science leaders say two actions this week in Washington D.C. threaten to put life science innovation up against the ropes. Continue reading
Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases
Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addressing the need to better characterize rare diseases.
TUCSON, Ariz. and WASHINGTON, September 19, 2019 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders® (NORD) launched the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) in Rockville, MD on Tuesday, Sept. 17. The platform, funded by a cooperative agreement through the Food and Drug Administration, [Critical Path Public-Private Partnerships Grant Number U18 FD005320], will provide data and analytics to aid in the understanding of rare diseases and to inform long-term drug development and support innovative trial designs.
Study Changes Guidelines for Sepsis Management
PHOENIX – A new study that measured the reliability of administering antibiotics before obtaining blood cultures could end the debate among physicians regarding sepsis management.Continue reading
Funded by FDA, C-Path and NORD to Launch Rare Disease Data Analytics Platform
The collaborative project between the organizations will kick off at a launch meeting in September and will aim to reduce barriers for the development of new treatments and cures for rare diseases
TUCSON, Ariz. and WASHINGTON, August 7, 2019 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders® (NORD) will host a meeting on Tuesday, September 17 in Bethesda, MD to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the Food and Drug Administration, [Critical Path Public-Private Partnerships Grant Number U18 FD005320 from the US Food and Drug Administration] the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases. The platform will provide the infrastructure for a sustainable, cooperative scientific approach to clinical trial readiness in rare diseases by addressing vast knowledge gaps about the natural course of disease, the clinical evaluation of new treatments, and patients’ perspective on disease and treatment.
Graduate Certificate Program in Regulatory Science Offered by UA Colleges of Law and Pharmacy and the Critical Path Institute Now Accepting Applications
Designed for graduate students and working professionals, the certificate program provides specialized training in navigating the path from research to bringing medical products to market.
TUCSON, Ariz., July 16, 2019 — The University of Arizona and the Critical Path Institute are urging students and working professionals to apply now for acceptance into their new online graduate certificate program designed to equip participants across multiple disciplines with core competencies in regulatory science. Regulatory science is the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of all products regulated by the U.S. Food and Drug Administration (FDA).
C-Path Taps Medical Science Operations Executive Kristen Swingle as Chief Operating Officer
TUCSON, Ariz., July 2, 2019 — The Critical Path Institute (C-Path) is pleased to announce that after an extensive search, it has appointed Kristen Swingle as its new Chief Operating Officer, effective July 1, 2019.
Swingle, who previously served as Vice President of Stem Cell Operations for Cord Blood Registry (CBR), a part of California Cryobank Life Sciences, specialized in newborn stem cell collection, processing and cryopreservation, brings nearly two decades’ worth of experience in the medical and molecular sciences industry to bear in her new role as she leads the daily operations of the organization and development and implementation of C-Path’s global strategy and goals.
New findings point to new treatments for Parkinson’s Disease
Parkinson’s disease (PD) affects 7-10 million people worldwide and is the leading movement-related disorder, causing progressive symptoms of rigidity and tremor. After Alzheimer’s, PD is the foremost neurodegenerative disease and efforts to prevent, treat or cure it have been arduous and frustrating.Continue reading
MIHS, Dignity Health, others form new health education alliance
Maricopa Integrated Health System (MIHS), Creighton University School of Medicine, Dignity Health St. Joseph’s Hospital and Medical Center, and District Medical Group, Inc., have announced a new alliance aimed at increasing the number of doctors and other health professionals in Arizona in order to meet the state’s growing demand for physicians and other healthcare professionals.Continue reading
Solera Health Secures $4 Million in Series A1 Funding
Investors Include BlueCross BlueShield Venture Partners, Sandbox Industries and SJF VenturesContinue reading